MARKET

TNDM

TNDM

Tandem Diabetes
NASDAQ

Real-time Quotes | Nasdaq Last Sale

71.14
-0.85
-1.18%
Pre Market: 69.95 -1.19 -1.67% 07:14 05/24 EDT
OPEN
72.25
PREV CLOSE
71.99
HIGH
72.84
LOW
69.46
VOLUME
372
TURNOVER
--
52 WEEK HIGH
155.86
52 WEEK LOW
67.03
MARKET CAP
4.55B
P/E (TTM)
818.64
1D
5D
1M
3M
1Y
5Y
DexCom - Insulet buyout deal unlikely, Bank of America says
Commenting on the reports that the medical device company DexCom (NASDAQ:DXCM) is in talks to acquire the insulin pump maker Insulet (NASDAQ:PODD), a group of analysts at Bank of America
Seekingalpha · 3h ago
Tandem Diabetes Care Announces Upcoming Virtual Conference Presentation
SAN DIEGO, May 18, 2022--Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a global insulin delivery and diabetes technology company, today announced that management will present a company update at the Piper Sandler Virtual Diabetes Symposium on Wednesday, May 2...
Business Wire · 5d ago
Citigroup Adjusts Tandem Diabetes Care's Price Target to $130 from $155, Keeps Buy Rating
MT Newswires · 05/17 13:23
Tandem Diabetes rises 3% on insider buying
Tandem Diabetes (TNDM) CFO, Leigh Vosseller buys 2500 common shares between the price range of $70-$76.6. CFO now holds 9118 common shares. CEO John Sheridan acquired 2500 common shares for the price of $69.90/share. CEO
Seekingalpha · 05/11 17:50
Is There An Opportunity With Tandem Diabetes Care, Inc.'s (NASDAQ:TNDM) 29% Undervaluation?
Today we will run through one way of estimating the intrinsic value of Tandem Diabetes Care, Inc. ( NASDAQ:TNDM ) by...
Simply Wall St. · 05/11 13:23
6 Analysts Have This to Say About Tandem Diabetes Care
Within the last quarter, Tandem Diabetes Care (NASDAQ:TNDM) has observed the following analyst ratings:
Benzinga · 05/05 19:27
Sector Update: Health Care
MT Newswires · 05/05 15:42
Tandem drags rival insulin pump makers as analysts cut targets after 1Q earnings
Tandem Diabetes Care (NASDAQ:TNDM) is trading sharply lower in the morning hours Thursday after the insulin pump maker posted mixed 1Q 2022 financials and at least four Wall Street analysts
Seekingalpha · 05/05 15:21
More
No Data
Learn about the latest financial forecast of TNDM. Analyze the recent business situations of Tandem Diabetes through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 13 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

15.38%Strong Buy
53.85%Buy
30.77%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average TNDM stock price target is 136.58 with a high estimate of 200.00 and a low estimate of 100.00.
High200.00
Average136.58
Low100.00
Current 67.47
EPS
Actual
Estimate
-0.13-0.030.070.16
Q2 2021
Q3 2021
Q4 2021
Q1 2022
Q2 2022
Institutional Holdings
Institutions: 506
Institutional Holdings: 71.34M
% Owned: 111.54%
Shares Outstanding: 63.96M
TypeInstitutionsShares
Increased
149
3.83M
New
61
997.91K
Decreased
112
4.79M
Sold Out
63
899.25K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Medical Equipment, Supplies & Distribution
-1.28%
Healthcare Equipment & Supplies
-1.39%
Key Executives
Chairman/Director
Kim Blickenstaff
President/Chief Executive Officer/Director
John Sheridan
Chief Financial Officer/Executive Vice President/Treasurer
Leigh Vosseller
Chief Operating Officer/Executive Vice President/Assistant Secretary
David Berger
Executive Vice President/Chief Administrative Officer
Susan Morrison
Executive Vice President
Elizabeth Gasser
Executive Vice President
Brian Hansen
Senior Vice President/Chief Compliance Officer/General Counsel/Secretary
Shannon Hansen
Senior Vice President
James Leal
Chief Technology Officer
Rick Carpenter
Lead Director/Independent Director
Dick Allen
Independent Director
Peyton Howell
Independent Director
Kathleen McGroddy-Goetz
Independent Director
Rebecca Robertson
Independent Director
Douglas Roeder
Independent Director
Rajwant Sodhi
Independent Director
Christopher Twomey
No Data
No Data
About TNDM
Tandem Diabetes Care, Inc. is a medical device company. The Company is engaged in designing, developing and commercialization of products for people with insulin-dependent diabetes. The Company’s manufacturing, sales and support activities principally focus on its flagship pump platform, the t:slim X2 Insulin Delivery System (t:slim X2), and its product offerings. The t:slim X2 is based on its technology platform and is capable of remote feature updates and is designed to display continuous glucose monitoring (CGM) sensor information directly on the pump home screen. Its products also include Basal-IQ technology and Control-IQ technology. The Basal-IQ technology is a predictive low glucose suspend feature that is designed to temporarily suspend insulin delivery to help reduce the frequency and duration of hypoglycemic events. Its Control-IQ technology is a hybrid-closed loop feature, designed to help increase a user's time in targeted glycemic range.

Webull offers kinds of Tandem Diabetes Care Inc stock information, including NASDAQ:TNDM real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, TNDM stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading TNDM stock methods without spending real money on the virtual paper trading platform.